New research indicates that early or severe male pattern baldness in men with untreated high blood pressure is linked to ...

Nektar Therapeutics is expected to announce topline data from the REZOLVE-AA trial in December 2025. The Food and Drug Administration (FDA) has granted Fast Track designation to rezpegaldesleukin for ...

Please provide your email address to receive an email when new articles are posted on . Rezpegaldesleukin is an interleukin-2 receptor pathway agonist that may stimulate regulatory T-cell expansion ...

Credit: SUN Pharma. Leqselvi is supplied as a tablet containing 8mg of deuruxolitinib. Prior to initiating treatment with Leqselvi, certain evaluations and immunizations are recommended. Leqselvi ™ ...

The FDA approved the oral Janus kinase (JAK) inhibitor deuruxolitinib (Leqselvi) to treat alopecia areata, drugmaker Sun Pharmaceutical announced on Thursday. The approval stipulates use of ...

This week, Melanie Sykes, 55, told followers on Instagram that she had returned to YouTube ‘after a long period of learning, ...

Kristen Whitney, DO, FAAD, determines systemic treatment options for severe alopecia areata based on the patient’s medical history, past treatments tried, potential adverse events, in addition to the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Baricitinib maintained hair regrowth among adolescents ...

Alopecia areata causes hair loss on the scalp or other body parts such as the eyebrows. New treatments like Olumiant offer hope for some people. This FDA-approved medicine works in unique ways to help ...